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Genetic studies into inherited and sporadic hemolytic uremic syn-
drome. Hemolytic uremic syndrome (HUS) in adults carries a high
morbidity and mortality, and its cause remains unknown despite many
theories. Although familial HUS is rare, it affords a unique opportunity to
elucidate underlying mechanisms that may have relevance to acquired
HUS. We have undertaken a genetic linkage study based on a candidate
gene approach. A common area bounded by the markers D1S212 and
D1S306, a distance of 26 cM located at 1q32 segregated with the disease (Z
max 3.94). We demonstrate that the gene for factor H lies within the
region. Subsequent mutation analysis of the factor H gene has revealed
two mutations in patients with HUS. In an individual with the sporadic/
relapsing form of the disease we have found a mutation comprising a
deletion, subsequent frame shift and premature stop codon leading to half
normal levels of serum factor H. In one of the three families there is a
point mutation in exon 20 causing an arginine to glycine change, which is
likely to alter structure and hence function of the factor H protein. Factor
H is a major plasma protein that plays a critical regulatory role in the
alternative pathway of complement activation. In light of these findings
and previous reports of HUS in patients with factor H deficiency, we
postulate that abnormalities of factor H may be involved in the etiology of
HUS.
Hemolytic uremic syndrome (HUS) is characterized by the
triad of the Coomb’s test-negative microangiopathic hemolytic
anemia, thrombocytopenia and acute renal failure. It exists in a
diarrheal-associated epidemic form (classified as d1 HUS), and
nondiarrheal (d2 HUS) sporadic and familial forms.
The d1 HUS form usually affects young children and they
recover spontaneously. Verocytotoxin is undoubtedly a primary
factor in the pathogenesis of the disease, but it is unclear why only
a percentage of children with the diarrhea (9 to 30% in the face
of E. coli 1057:H7 [1]) develop the syndrome.
Sporadic, noninfective HUS usually affects adults and generally
carries a worse prognosis. Predisposing factors include the oral
contraceptive, cyclosporine, quinine, pregnancy, tumors and con-
nective tissue disorders, but it is often idiopathic.
The familial form of the disease is rare but affords a unique
opportunity to elucidate underlying mechanisms that may have
relevance to acquired and epidemic HUS. The majority of fami-
lies reported are recessive, but dominant inheritance has also
been reported [2, 3].
Since the first description by Gasser et al in 1955 [4], many
theories have been suggested for the cause of nondiarrheal HUS.
These have included altered prostacyclin metabolism [5], unusual
von Willebrand factor multimers [6], increased levels of plasmino-
gen-activator inhibitor 1 [7], the presence of platelet activating
and agglutinating factors [8, 9], and increased complement activity
[10–12]. Because the disease recurs in renal allografts and re-
sponds in some individuals to plasma exchange it is probable that
a plasma factor is in part responsible. In this study we present
compelling new evidence from three families with inherited HUS
and one individual with sporadic HUS that the primary abnor-
mality is overactivity of the alternative complement pathway.
Family pedigrees and clinical histories
Hemolytic uremic syndrome was defined in our families by the
presence of acute renal failure and at least two of the following:
characteristic histopathological findings on biopsy or at post
mortem, acute anemia, thrombocytopenia, and fragmented red
cells on blood film. Several individuals in each family exhibited all
five features.
Families. Family 1 was first described in 1975 [13], and since
then three further family members have been affected (Fig. 1). In
addition to the classical hematological and histological features of
HUS, severe hypertension and recurrence in renal allografts has
occurred.
Family 2a has already been described in part [14]. Two other
families with familial HUS were found to live within a few miles,
and we have established a common lineage for one dating back to
the start of the last century. The other, family 2b, probably has the
same lineage but we have been unable to definitively establish this
premise (Fig. 1). Clinical features are similar to family 1, including
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some individuals with hypertension requiring bilateral nephrec-
tomy. However, two family members have renal allografts func-
tioning well after seven and eight years.
Family 3 (Fig. 1) has been described in detail [15]. Three male
siblings were affected at ages 27, 31 and 35, and all three have had
successful renal transplants with no recurrence of disease.
Sporadic case. A male with sporadic/relapsing HUS presented
at the age of 36 with a one week history of malaise, nausea, loin
Fig. 1. Pedigrees of family 1, 2a and 2b, and 3. It is likely that families 2a and 2b are related to each other. The microsatellite results for eleven
chromosome 1 loci are aligned beneath the pedigree symbols for the five individuals from family 2a included in the linkage analysis and for IV 2 of family
2b who was not included in the linkage analysis. A common haplotype extending from D1S240 to D1S2738 is boxed. The symbol/between alleles
indicates that it is not clear which is the maternal allele and which is the paternal allele. In family 3 the affected individuals are haploidentical for the
markers extending from D1S212 to D1S249.
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ache and anorexia. He was profoundly anemic (Hb 6.9 g/dl),
thombocytopenic (79 3 109/liter), hypertensive, and in advanced
acute renal failure. Renal biopsy revealed a thrombotic microan-
giopathy consistent with HUS, and immunohistochemistry
showed deposition of C3 in vessel walls. C3 levels were decreased
(0.59 g/liter, NR 0.65 to 1.7) with normal levels of C4, consistent
with activation of the alternative pathway. Despite treatment with
a short course of plasma exchange and angiotensin II converting
enzyme inhibitors he failed to regain renal function.
Fifteen months post-presentation he received a cadaveric renal
allograft, under cover of anti-thymocyte globulin and subse-
quently cyclosporine based immunosuppression. Despite a good
early urine output the graft function deteriorated acutely on day
24 post-transplantation, and allograft biopsy showed recurrent
HUS. There was an improvement with plasma exchange, but this
was not sustained and the graft eventually failed, requiring
nephrectomy three months later. He is currently being treated
with hospital based hemodialysis.
His mother has no relevant medical history and his father is
deceased (CVA).
METHODS
The study was approved by the Joint Ethics Committee, Uni-
versity of Newcastle upon Tyne and Newcastle and North Tyne-
side Health Authority.
DNA extraction
Genomic DNA was isolated from whole blood using the
nucleon 2 DNA extraction kit (Scotlab Bioscience, UK). Archival
tissue was obtained from paraffin-embedded microscope slides
and tissue blocks with the consent of the nearest family members.
Twenty micromolar sections of tissue blocks and scrapings from
microscope slides were deparaffinized with xylene and washed in
ethanol. These were then digested overnight with proteinase K.
The proteinase K was then heat inactivated at 95°C for 10
minutes, the sample centrifuged, and aliquots of supernatant used
directly for polymerase chain reaction (PCR) amplification.
Microsatellite polymorphism genotyping
Microsatellite polymorphism primers were obtained from the
‘Human Screening Panel’ (Research Genetics) or synthesized in
the University Facility for Molecular Biology, University of New-
castle upon Tyne. Microsatellite polymorphisms flanking or within
the genes for prostaglandin synthase 2 (PTGS 2 or COX 2,
chromosome 1q25.2–25.3) the inducible gene involved in prosta-
cyclin synthesis, von Willebrands Factor (vWF, chromosome 12p
13.2–13.3), tissue factor (TF, chromosome 1p21 to 22), plasmin-
ogen activator inhibitor 1 (PAI 1, chromosome 7q 22.1–22.3), the
selectin gene cluster (SEL, chromosome 1q22 to 25) and comple-
ment factor H (HF, chromosome 1q32) were studied in a candi-
date gene approach to linkage analysis in the 3 families.
100 ng of genomic DNA template (previously aliquoted and
dried at 65°C onto 96 well microtiter plates) was amplified in total
volumes of 10 ml containing 1.3 pmol 32P end-labeled 39 primer
(0.3 mCi gamma 32P ATP (Amersham) and T4 polynucleotide
kinase/buffer (New England Biolabs)), 1.3 pmol 59 primer, 0.15 u
Taq polymerase and 1.5 mM Mg21 buffer (Promega) and 2 pmol
dNTPs overlaid with 1 drop of mineral oil. The standard pro-
gramme profile was denaturation 94°C for four minutes, followed
by 30 cycles of 94°C denaturation -one minute, 55°C annealing -
one minute, 72°C extension- one minute and a final extension step
of 72°C for 10 minutes. The standard annealing temperature was
55°C, although a range of temperatures from 50 to 60°C were
required to optimize the reaction. PCR of template obtained from
paraffin embedded tissue usually required either more PCR cycles
(40 to 60) or a double PCR technique using an aliquot of first
round product. PCR fragments were resolved on a 6% denaturing
polyacrylamide gel.
Linkage analysis
Those included in the linkage calculation are indicated in
Figure 1, including in family 1 individuals designated I-2 and II-2,
in whom genotype could be inferred although DNA was not
available. Multipoint linkage analysis was carried out using the
FASTLINK program of the LINKAGE package [16].
For the purposes of the analysis HUS was assumed to be
inherited as an autosomal dominant trait with incomplete pen-
etrance, and a gene frequency in the general population of 0.0001.
Fig. 2. Multipoint linkage map of the results from the three families.
Chromosome 1q loci and the sex averaged distances (cM) between them
are shown beneath
Fig. 3. This Figure shows the position of the gene for factor H relative to
the region of chromosome 1 segregating with HUS in these three families.
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Family members who were asymptomatic at the time of analysis
(family 1 - II-6, III-2 and III-3, family 3 - II-3 and II-5) were given
an age related liability score based on age at onset in affected
members in family 1. Such an assumption was justified in the
absence of any obvious peaks in the age of patients at onset of
disease. The parents in family 3 (I-1 and I-2) were assigned
liability scores of 0.5.
As we were unable to confirm the relationship of family 2b to
family 2a, it was not included in the linkage analysis.
mRNA Extraction and cDNA Synthesis
Messenger RNA was extracted from peripheral blood leuko-
cytes (Quickprep microRNA purification kit - Pharmacia Bio-
tech). Reverse transcription was performed on oligo (dT) pooled
RNA (Reverse transcription system- Promega) in a total volume
of 40 ml for one hour, as described. Product was heated to 95°C for
five minutes followed by incubation at 0°C for five minutes to
inactivate the reverse transcriptase.
RT-PCR and SSCP (single strand conformational
polymorphism) analysis of Factor H polymorphisms
Sections of the HF gene were amplified from 2 ml of cDNA
product in a total volume of 100 ml containing 100 pmol each of
forward and reverse primers (sequences available on request), 20
pmol dNTPs and 2.5 u Taq polymerase and 1.5 mM Mg21 buffer
(Promega). Reaction conditions consisted of four minutes dena-
turation, 30 cycles of one minute denaturation, one minute
Fig. 4. (a) SSCP (single stranded conformational polymorphism) appearance of exon 20 amplicon in affected individuals of family 2, and controls (C).
Note the band shifts representing a mutation in the factor H gene. (b) Part of exon 20 codon sequence (numbered according to [32]), demonstrating
the mutation in affected members of families 2a and 2b, with corresponding amino acid product, and mutated polypeptide.
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annealing and one minute extension (annealing temperature as
listed) and a final 10 minutes extension step. A ‘touchdown’ PCR
technique was used to reduce spurious priming. Individual ampli-
cons were amplified via further rounds of PCR using nested
primers and 2 ml of the first round product.
SSCP was performed using 4 ml of final product, added to 6 ml
of formamide loading buffer and denatured for three minutes
before cooling on ice. This final mixture was electrophoresed in a
1X Hydrolinky gel (J. T. Baker) with 2.5–5.0% glycerol at 10 to 25
mA for 18 to 24 hours. Gels were then silver stained.
We have previously discovered a novel polymorphism in the
gene for factor H, located in exon 5 [17]. This was studied by SSCP
analysis in the 3 families. Intraexonic primers for exons 1 and 20
were designed to facilitate screening of 60 healthy volunteers
using genomic DNA as template.
Sequencing
PCR products containing an aberrant SSCP band were sub-
cloned into pTAg plasmid (Ligator, Ingenius) and DNA was
extracted using a commercial kit (Wizard minipreps, Promega).
Using the same primers and conditions, PCR and SSCP were
repeated alongside parent PCR product to ensure integrity of
inserts. 3 separate clones containing inserts of the aberrant band
were sequenced on an ABI Prism 377 DNA sequencer using
dye-labeled M13 forward and reverse primers.
Complement studies. C3 and C4 were measured by nephelom-
etry using a Beckman Array 360 immunochemistry system. Fac-
tors B and H were measured by single radial immunodiffusion
(Binding Site Ltd, Birmingham). CH100 and AP 100 were mea-
sured using gel haemolytic assays according to standard protocols
[18].
RESULTS
Linkage data
The multipoint linkage analysis between disease and markers
on chromosome 1q is shown in Figure 2. No recombinations were
seen between the disease and a haplotype extending from D1S212
to D1S306 in all three families. The maximum lod score is 3.94.
The data from family 2 is a significant underestimation of the
‘true’ lod score as we were unable to include family 2b which was
subsequently found to have the same mutation.
The three affected members of family 3 share an identical
genotype profile across the region, compatible with either a
dominant or recessive form of inheritance (Fig. 1). Analyzing the
data from this family on a dominant model gave a conservative
estimate of the lod score; for example for D1S2757 the 2 point lod
score for this family is 0.75 assuming dominant inheritance and
1.27 assuming recessive inheritance.
A novel polymorphism in the factor H gene was informative in
family 1 and allowed us to confirm that factor H maps within the
region (Fig. 3).
Mutation analysis
Mutations were sought in the coding region of factor H by
single strand conformational polymorphism (SSCP) and hetero-
duplex analysis of RT-PCR amplified fragments, using mRNA
extracted from peripheral blood leukocytes as template and a
multiple PCR technique with nested primers.
A band shift was located in an amplicon containing part of exon
19 and exon 20 in affected members and obligate carriers of family
2a and 2b. Subcloning and sequencing of the mutant band
revealed a point mutation (C3G transversion) causing an argi-
nine 3 glycine change in exon 20 (R1197G) (Fig. 4). We have
screened 60 healthy controls by PCR/SSCP with intraexonic exon
20 primers using conditions which clearly demonstrate the above
transversion and no band shifts were seen. No band shifts were
Fig. 5A. SSCP [1] and Heteroduplex [2] appearance of exon 1 amplicon
in affected individual with relapsing HUS. Note the band shifts repre-
senting a mutation in the factor H gene. (B) Part of exon 1 codon sequence
in the individual with sporadic/relapsing HUS (numbered according to
[32]), demonstrating the deletion, frame shift and premature stop codon
with corresponding amino acid product, and truncated polypeptide.
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detected in the coding region of the gene in patients from families
1 and 3.
A band shift was located in an amplicon containing exon 1 and
part of exon 2 in the sporadic case. Sequencing of the mutant band
revealed a 4 base pair deletion in exon 1 causing a frame shift and
subsequent premature termination codon (Fig. 5). The mutation
is most clearly demonstrated using intraexonic primers and
genomic DNA as substrate, and was not found in 60 healthy
controls under these conditions. Microsatellite polymorphism
profiles and mutation analysis from surviving family members
suggest that the mutation was either inherited from the patient’s
father (who died of a cerebrovascular accident - no other infor-
mation available, and no further paternal family members avail-
able to study) or represents a new mutation.
Complement profiles. Complement studies of both affected and
unaffected family members taken during disease free periods are
shown in Table 1. In family 1 it is of note that both affected
individuals and a disease free obligate gene carrier demonstrate
relatively lower C3 levels than non gene carriers. This was not
seen in family 2. Factor H levels are not significantly depressed in
any of the families.
A full complement profile from the individual with sporadic
HUS, taken five years after initial presentation and in the absence
of evidence of active disease, is shown in Table 1. As well as low
levels of factor H, both C3 and factor B are markedly reduced in
keeping with activation of the alternative pathway.
DISCUSSION
To gain insight into the etiology of HUS we have undertaken a
linkage study using a candidate gene approach to the familial form
of HUS. In the 3 families HUS maps to a region of one of our
candidate genes - that of complement factor H. In one of these
families we found a mutation in this candidate gene. We have also
found a mutation in a sporadic case. These findings represent the
first reported molecular evidence of the involvement of factor H
in the disease.
In a review of the literature, factor H deficiency in HUS has
been recorded in 3 previous reports. The first reported deficiency,
by Thompson and Winterborn in 1981 [19], was of an eight
months old boy who presented with HUS and his healthy three
years old brother who both had 5 to 10% of the normal level of
factor H, inherited in an autosomal recessive fashion from
consanguineous parents, each of whom had approximately 50%
normal levels. Roodhooft et al in 1990 [20] described a female
infant who suffered 3 recurrent episodes of HUS (including an
ultimately fatal recurrence following renal transplantation) and
had 48% of normal levels of factor H apparently inherited from
her unaffected father who had 34% of normal levels.
Thirdly, Pichette et al in 1994 [21] reported a family in whom
two siblings suffered HUS: one of whom died at an early age from
diarrhoeal associated HUS (E. coli serotype 0119B14) and a
female sibling who had suffered 3 episodes of HUS since the age
of 19 and was also shown to have an autosomal recessive
deficiency of factor H (5% of normal levels). An asymptomatic
sister was found to have only 5% levels and several members of
the extended family had approximately 50% levels. It is therefore
possible that both autosomal recessive and autosomal dominant
HUS are associated with abnormalities of factor H.
Normal levels of factor H do not exclude an underlying
functional abnormality and the finding of a mutation in factor H
Fig. 5. Continued.
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in only one of the three families (family 2) may reflect the relative
insensitivity of SSCP in detecting mutations (sensitivity approxi-
mately 65 to 75%). Certainly the finding of persistently lower C3
levels in both previously affected individuals and an unaffected
obligate gene carrier in family 1 is interesting in this context.
Recently, a family of human plasma proteins has been identified
which are related structurally and immunologically to factor H
and which map to the same area of chromosome 1 [22], and these
genes would be candidates if mutations are not identified in
families 1 and 3 after completing exhaustive mutation analysis.
Factor H is a major plasma protein, being present at a
concentration of approximately 300 to 600 mg/l. It is synthesized
mainly in the liver, but smaller amounts are generated by endo-
thelium and macrophages. It is found in platelets and is mem-
brane bound on some leukocytes [23]. Factor H has several
important regulatory roles in the activity of the alternative path-
way [23]; firstly, by binding with C3b, preventing the formation of
the C3bBb (C3 convertase) complex and accelerating the dissoci-
ation of Bb from the active C3 convertase (so called decay-
accelerating activity) [24, 25]; secondly, by acting as a cofactor for
factor I, a serine protease, which degrades C3b by cleaving the
alpha chain of C3, converting it into the major opsonic form, iC3b
[25]; and thirdly, by distinguishing between activator and non-
activator surfaces [26].
The single polypeptide chain of factor H is composed of 20
small independently folding units known as short consensus
repeats (SCRs), each approximately 60 amino acids in size and
generally coded for by single exons. Correct folding of SCRs is
crucial to function (for example breakage of disulphide bonds of
factor H results in complete loss of cofactor activity [27]) and even
single amino acid substitutions can significantly alter function (for
example His3Asp at position 1106 in the C4b molecule [28],
which is also composed of SCRs).
We describe the finding of two mutations in the gene for factor
H. The first, in family 2 comprises a single base substitution in
exon 20 causing an arginine to glycine change in SCR20. Recently
a domain encompassing SCRs 16 to 20 has been shown to bind
C3b [29] and it is of note that SCRs with structural homology to
19 and 20 are located at the C-terminal end of all human and the
majority of mouse factor H and H-related proteins [22]. This
arginine shows positional conservation in 3 of the 5 human and 3
of the 4 murine terminal SCRs. Arginine is a basic amino acid
with a polar side chain and its substitution by the uncharged
glycine, often a pivotal point in polypeptides, may significantly
affect structure and thus function. The second mutation in an
individual with relapsing HUS comprises a deletion causing a
frame shift and subsequent premature termination codon which
leads to approximately 50% levels of serum factor H.
In order to explain disease associated with haploinsufficiency
for factor H - as in our sporadic case one would have to postulate
a ‘dose effect’ which possibly becomes important following an
environmental trigger such as a drug or an infection. Precedent
exists within the complement pathway. Haploinsufficiency for C1
esterase inhibitor predisposes to angioneurotic edema. In this
condition there is a high rate of de novo mutations, demonstrating
that a negative family history does not necessarily exclude a
genetic cause. This may have relevance to sporadic HUS in
general and our patient in particular. However in this context it is
interesting that in the previously described families with homozy-
gous factor H deficiency HUS is not seen in heterozygotes.
Perhaps the nature of the genetic mutation causing the deficiency
of factor H may be relevant or the activity of the remaining factor
H may vary (there are known to be several polymorphic forms of
the factor H protein and we have identified several genetic
polymorphisms within the gene [17]). Deficiency of factor H has
also been associated with SLE like collagen vascular disease,
increased susceptibility to infection and glomerulonephritis [23].
Table 1. Serum complement profiles of family members
Family Subject Status
C3
0.68–1.8 g/liter
C4
0.18–0.60 g/liter
Factor B
191–382 mg/liter
Factor H
345–590 mg/liter CH100 AP100
1 II-1 Unaffected 1.23 0.34 256 665 N N
1 II-2 Unaffected 1.00 0.27 247 648 N N
1 II-3 Unaffected 1.51 0.42 N/A N/A N/A N/A
1 III-1 Affected 0.55 0.22 265 532 N N
1 IV-1 Affected 0.67 0.22 256 548 N N
1 III-6 Carrier 0.72 0.22 265 532 N N
2a IV-11 Unaffected 0.92 0.22 372 517 N N/L
2a IV-23 Unaffected 1.27 0.24 293 564 N N
2a IV-12 Affected 0.75 0.22 165 486 N N/L
2b IV-1 Unaffected 1.27 0.24 293 564 N N
2b IV-2 Affected 1.16 0.27 247 648 N N
2a IV-3 Carrier 0.98 0.23 274 548 N N
3 II-2 Affected 80% N/A N/A N/A N/A N/A
3 II-4 Affected 51% N/A N/A 68% N/A N/A
3 II-6 Affected 76% N/A N/A 80% N/A N/A
Individual Affected 0.4 0.25 157 222 N N
‘Carrier’ refers to individuals who are obligate gene carriers but have not suffered HUS; ‘N’ and ‘N/L’ are normal and at the lower end of normal
range; N/A is not available. Levels of C3 and H from family 3 are expressed as a percentage (of a standard level obtained from a panel of unaffected
control sera). All samples were taken during periods of good health, and in the absence of evidence of active HUS.
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In a pig model of inherited factor H deficiency homozygotes
develop a lethal mesangioproliferative glomerulonephritis [30].
In two of the three families complement profiles were normal.
It is possible that the response to activation of the alternative
pathway could be exaggerated in the presence of factor H
mutations despite normal basal activity.
Factor H would fit the profile of an agent involved in the
etiology of HUS. Recurrence of disease in renal allografts,
especially early recurrence, suggests a plasma factor, as does
improvement following plasma exchange. Abnormal levels of
complement factors, particularly factors B and C3 are often found
in active d- HUS suggesting overactivity of the alternative path-
way. Although it is abnormalities of factor H that we have shown
to be associated with HUS, it is possible that abnormalities of
other regulators of the alternative pathway, such as factor I, could
also be implicated.
Are these findings of any relevance to the pathogenesis of the
more commonly seen but histologically distinct d1 HUS ? There
is evidence to suggest that there is increased complement activa-
tion in this condition. Two studies of children with d1 HUS show
that low C3 levels are associated with a poor prognosis [11, 31].
Moreover, in another study increased breakdown products of C3
and factor B were found suggesting activation of the alternative
complement pathway [12]. It is of interest that in the factor H
deficient sibling pair who suffered with HUS described by
Pichette, one presented with d1 HUS and the other with d-HUS.
It is known that there are polymorphisms of the factor H protein
and we have previously described a polymorphism in an NF kappa
B responsive element in the promoter region of the gene [17]. It
is intriguing to speculate that some of these polymorphic variants
confer a genetic predisposition to d1HUS.
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NOTE ADDED IN PROOF
Mutations in the factor H gene have recently been described in a factor
H deficient child with membranoproliferative glomerulonephritis [33].
Reprint requests to Dr. Timothy H.J. Goodship, Department of Medicine,
University of Newcastle upon Tyne, Queen Victoria Road, Newcastle upon
Tyne, England NE1 4LP, United Kingdom.
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